iShares USDBond UCITS ETF (id:5333 LQDA)

10.65 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 11:01:52 AM)

Exchange closed, opens in 1 day 22 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• 5 years
• All

About iShares USDBond UCITS ETF

Market Capitalization 832.82M

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.